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Abstract
Biological and mechanistic relevance of intergenic disease-associated genetic loci (IDAGL) 
containing highly statistically significant disease-linked SNPs remains unknown. Here we present the 
experimental and clinical evidence revealing important role of IDAGL in human diseases. Targeted 
RT­PCR screen coupled with sequencing of purified PCR products detects widespread transcription 
at multiple intergenic disease­associated genomic loci (IDAGL) and identifies 96 small non­coding 
trans­regulatory RNAs of ~ 100-300 nt in length containing SNPs associated with 21 common human 
disorders (snpRNAs). Functionality of snpRNAs is supported by multiple independent lines of 
experimental evidence demonstrating their cell-type-specific expression and evolutionary 
conservation of sequences, genomic coordinates, and biological effects. Analysis of chromatin state 
signatures, expression profiling experiments using microarray and Q-PCR technologies, and 
luciferase reporter assays indicate that many IDAGL are Polycomb-regulated long-range enhancers. 
Expression of snpRNAs in human and mouse cells markedly affects cellular behavior and induces 
allele-specific clinically-relevant phenotypic changes: NLRP1-locus SnpRNAs exert regulatory effects 
on monocyte/macrophage trans-differentiation, induce prostate cancer (PC) susceptibility SnpRNAs, 
and transform low-malignancy hormone-dependent human PC cells into highly malignant androgen-
independent PC. Q-PCR analysis and luciferase reporter assays demonstrate that snpRNA 
sequences represent allele-specific “decoy” targets of microRNAs which function as SNP-allele-
specific modifiers of microRNA expression and activity. We demonstrate that trans-acting RNA 
molecules facilitating androgen depletion-independent growth (ADIG) in vitro and castration-resistant 
(CR) phenotype in vivo of PC contain intergenic 8q24-locus SNP variants which were recently linked 
with increased risk of developing PC. Expression level of 8q24-locus PC susceptibility snpRNAs is 
regulated by NLRP1-locus snpRNAs, which are transcribed from the intergenic long-range enhancer 
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sequence located in 17p13 region at ~ 30 kb distance from the NLRP1 gene. Q-PCR analysis of 
clinical PC samples reveals markedly increased snpRNA expression levels in tumor tissues 
compared to the adjacent normal prostate [122-fold and 45-fold in Gleason 7 tumors (p = 0.03); 370-
fold and 127-fold in Gleason 8 tumors (p = 0.0001); for NLRP1-locus and 8q24-locus SnpRNAs, 
respectively]. Highly concordant expression profiles of the NLRP1-locus snpRNAs and 8q24 CR-
locus snpRNAs (r = 0.896; p < 0.0001) in clinical PC samples and experimental evidence of trans-
regulatory effects of NLRP1-locus snpRNAs on expression of 8q24-locus SnpRNAs indicate that 
ADIG and CR phenotype of human PC cells can be triggered by RNA molecules transcribed from the 
NLRP1-locus intergenic enhancer and down-stream activation of the 8q24-locus snpRNAs. Our 
results define the intergenic NLRP1 and 8q24 regions as regulatory loci of ADIG and CR phenotype 
of human PC, reveal previously unknown molecular links between the innate immunity/inflammasome 
system and development of hormone-independent PC, and identify novel diagnostic and therapeutic 
targets exploration of which should be highly beneficial for clinical management of PC. 
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Introduction
Meta-analysis of genomic coordinates of nearly 800 significant SNP-phenotype associations 
(P<5x10-8) identified in nearly 600 genome-wide association studies (GWAS) of 150 distinct diseases 
and traits demonstrates that only 12% of identified to date disease-linked SNPs are located within 
exons of protein-coding genes (or occur in tight linkage disequilibrium with protein-coding regions of 
genes) and a vast majority (80%) of variations occurs within non-protein-coding sequences (1). These 
findings are particularly striking because SNPs in protein-coding regions are heavily over-represented 
on genotyping arrays (2, 3) which further highlight the significant knowledge gap in our understanding 
the role of intronic and intergenic sequences in regulation of phenotypes. Intergenic SNPs, which are 
located in genomic regions distant from known protein-coding genes and microRNAs, comprise 40% 
and represent the largest class of SNP variations with significant associations to multiple common 
human disorders (4). Recently we reported identification of thirteen intergenic small trans-regulatory 
RNAs (trans-RNAs) containing disease-linked SNPs and manifesting cell type-specific patterns of 
expression in human cells (4). Functional analysis of one of these trans-RNAs, which are transcribed 
from the intergenic sequence located in 17p13 region at ~30 kb distance from the NLRP1 gene and 
termed NLRP1-locus snpRNA, demonstrates SNP allele-specific biological effects of trans-RNAs on 
cell cycle progression, differentiation, and gene expression in human cells (4). These initial 
observations indicate that intergenic disease-associated genetic loci (IDAGL) are transcriptionally 
active and may influence the biological behavior of human cells via non-coding RNA intermediaries. 
Several independent GWAS identified prostate cancer susceptibility SNPs within the 8q24 
gene desert (5–12), which were subsequently classified into three adjacent genomic regions of 
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increased risk for prostate cancer (13). These regions contain multiple prostate cancer risk SNPs with 
the most significant and convincingly replicated SNPs being rs1447295 in region 1, rs16901979 in 
region 2, and rs6983267 in region 3 (13). Consistent with the hypothesis of biological significance of 
IDAGL, several groups reported that multiple long-range enhancers are present within genetically-
defined prostate cancer risk regions of the 8q24 gene desert (14-18) and demonstrated functional 
correlations of enhancer’s activity with prostate cancer risk SNP sequences. 
In this work we report sequences of 96 snpRNAs which are transcribed from IDAGL that were 
discovered in association studies of common human disorders and replicated in independent cohorts 
of patients (Supplemental references 1-43). Functional analyses of snpRNAs associated with prostate 
cancer reveal novel genome-wide trans-regulatory networks of non-coding snpRNAs which are 
transcribed from long-range enhancers and facilitate development of castration-resistant phenotype 
of human prostate cancer. Our experiments indicate that activation of the NLRP1-locus snpRNA/miR-
205 axis may contribute to development of clinically-significant prostate cancer by reducing 
expression of the PTEN tumor suppressor. 
Results
IDAGL generate evolutionary conserved small non-coding snpRNAs and display common 
chromatin state signatures.
To date, we analyzed 109 IDAGL using targeted RT-PCR-based screening protocol which is 
designed for identification of RNA molecules containing disease-associated SNP sequences (4).  We 
identified 96 trans-regulatory RNAs (snpRNAs) 100 to 300 nucleotides in length containing intergenic 
SNPs which are associated with 21 common human disorders (Supplemental Tables S1-S9). 
Molecular identities of discovered RNA molecules were established based on a requirement of 
reverse-transcription for detection of expected size PCR products and confirmed by size 
correspondence, sensitivity to RNAse treatment and resistance to DNAse treatment of primary PCR 
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products and nested PCR products which were derived from second round of amplification of purified 
primary PCR products. In all instances molecular identities of discovered RNA molecules were 
validated by direct sequencing of purified primary PCR products (Supplemental Tables S6-S9). 
Considering the evidence of evolutionary conservation as one of the important criteria 
supporting the hypothesis of functionality of discovered snpRNA molecules, we analyzed a set of 13 
IDAGL, which generate evolutionary conserved snpRNAs. Notably, 9 of 13 (70%) of evolutionary 
conserved intergenic sequences manifest common genomic topologies in the mouse and human 
genomes that is snpRNA-encoding sequences in both species have the same flanking protein-coding 
genes (Supplemental Figure S1). We made use of the extensive genome-wide chromatin domain 
maps (19, 20) to assess the chromatin state of evolutionary conserved IDAGL. This analysis reveals 
a consensus chromatin signature of evolutionary conserved snpRNA-encoding IDAGL comprising 
H3K27Me3, CBP/CREB, and POL2 proteins (Supplemental Figure S2), which indicate that IDAGL 
may represent a distinct class of Polycomb-regulated enhancers. Consistent with this notion, many 
evolutionary conserved snpRNA-encoding IDAGL display enhancer’s signature H3K4me1 histone 
marks (Supplemental Figure 2), whereas histones H3K4Me3 and H3K36Me3, which represent 
chromatin signatures of promoters and transcriptionally active sites (21-23), appear less frequently. 
We confirmed the validity of these findings for both evolutionary-conserved and non-conserved 
IDAGL by performing the analysis of the chromatin state maps of IDAGL in human embryonic stem 
cells, ESC (Supplemental Figures 1-3; Supplemental Table S10). Based on this analysis we 
concluded that nearly ubiquitous chromatin state signature of IDAGL in human ESC consists of 
histone H3K27me3 and Ezh2 protein (Supplemental Figures 2 and 3). In addition to consensus 
components, the IDAGL chromatin maps display clearly discernable disorder-type-specific protein 
marks which manifest common association patterns for pathogenetically- and epidemiologically-
related disease phenotypes (Supplemental Figure S4; Supplemental Table S10). Analysis of 
ENCODE chromatin state maps in 9 human cell lines validates this conclusions and reveals a 
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consensus chromatin signature of IDAGL comprising H3K27Me3 and H3K4Me1 histones, Ezh2, and 
disease-state-specific panels of transcription factors (http://genome.ucsc.edu/ENCODE/ ). 
Expression of NLRP1-locus snpRNAs induces clinically-relevant phenotypic changes in 
human cells.
Given that SNP-phenotype associations can result from tagging and may therefore not 
necessarily indicate the true causal relationships, we thought to undertake the functional analysis of 
selected snpRNAs to show that snpRNA-mediated phenotype altering effects on cellular behavior 
reflect their role in diseases. Functional analysis of human cell lines engineered to constitutively 
express distinct allelic variants of NLRP1-locus snpRNAs revealed marked changes of biological 
behavior of cells expressing disease-associated allelic variants of snpRNAs which are consistent with 
targeted alterations of cell cycle progression/differentiation pathways (4). To ascertain whether 
changes of cellular functions caused by forced expression of NLRP1-locus snpRNAs are consistent 
with their suspected role in diseases, we analyzed monocyte/macrophage trans-differentiation of 
human THP-1 cells constitutively expressing 52 nt NLRP1-locus snpRNAs containing either 
ancestral, major A allele or disease-linked, minor G allele (Figure 1). We found that G-allele 
expressing THP-1 cells, in contrast to control or A-allele expressing cells, undergo massive apoptosis 
during differentiation process and are capable to generate 5-fold less macrophages compared to A-
allele expressing cells (Figure 1A). Expression of snpRNAs containing ancestral A-allele confers 
protection against apoptosis and facilitates production of nearly two-fold more macrophages 
compared to control cells (Figure 1A). Notably, macrophages derived from A-allele-expressing THP-1 
cells manifest significantly more potent phagocytic activity compared to control cells or macrophages 
derived from G-allele-expressing THP-1 cells (Figure 1A, inset). These phenotypic changes are not 
due to the generally diminished cellular functions because G-allele expressing cells manifest a 
7
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
06
9.
1 
: P
os
te
d 
27
 J
un
 2
01
1
sustained long-term viability in optimal growth conditions and have significantly higher motility 
compared to the control cultures and A-allele expressing cells (Figure 1B).
Next we thought to determine whether the evolutionary conservation of NLRP1-locus snpRNAs 
is sufficient to facilitate the similar biological effects on mouse cells. We found that human NLRP1-
locus snpRNAs exert biological effects on mouse macrophages and mesenchymal cells which are 
strikingly similar to that documented for human cells (Figure 1C, top panels). Furthermore, the allele-
specific biological effects of forced expression NLRP1-locus snpRNAs mediated by the lentiviral gene 
transfer can be readily reproduced by transfection of synthetic LNA oligonucleotide analogues of 
snpRNA molecules (Figure 1C, bottom panels). Based on these observations we conclude that 
substitution of a single nucleotide in snpRNA molecules may cause dramatic alterations of cell’s fate 
and results in marked changes of cellular phenotypes of potential clinical relevance. 
NLRP1-locus snpRNAs transform low-malignancy hormone-dependent human PC cells into 
highly malignant castration-resistant PC by inducing 8q24-locus PCS-snpRNAs.
Q-RT-PCR expression profiling experiments reveal that NLRP1-locus snpRNAs markedly alter 
the expression of prostate cancer susceptibility (PCS) snpRNAs in human cells (Figure 2), which 
suggest that extensive phenotypically-relevant regulatory cross-talk may exist between distinct 
classes of snpRNAs. We noted particularly interesting patterns of association between expression of 
NLRP1-locus snpRNAs and 8q24-locus PCS-snpRNAs A6, expression of which appears elevated in 
highly metastatic variants of human prostate cancer cell lines as well as prostate cancer cell lines 
selected for growth in androgen-free media (Figure 2). To confirm that observations of clinically-
relevant biological effects of IDAGL snpRNAs are not limited to the NLRP1-locus snpRNAs, we 
analyzed the effect of forced expression of distinct allelic variants of PCS-snpRNAs on behavior of 
hormone-dependent human prostate carcinoma cell line LNCap cultured under various growth 
conditions. We found that expression of both NLRP1-locus and PCS-snpRNAs have no effect on 
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growth of LNCap cells in adherent cultures (data not shown), whereas the anchorage-independent 
growth potential of LNCap cells in agar was markedly enhanced by PCS-snpRNAs A6, which was 
more significant for PCS-snpRNAs containing the prostate cancer susceptibility allele (Figure 2C). 
Human prostate carcinoma LNCap cells are hormone-dependent and are not capable of growing in 
androgen-free media (Figure 2C). Intriguingly, when we cultured in androgen-free conditions LNCap 
cells engineered to stably express snpRNAs, we found that expression of either NLRP1-locus 
snpRNAs or PCS-snpRNAs A6 facilitates hormone depletion-independent growth of LNCap cells 
(Figure 2C). 
Highly metastatic LNCapLN3 cells which were selected for increased metastatic potential by 
serial orthotopic re-implantation after recovery from metastatic lesions acquire markedly increased 
ability to grow in agar and in androgen-depleted media (Figure 2C, insets). Q-RT-PCR expression 
profiling analysis reveals that LNCapLN3 cells manifest markedly higher expression level of the PCS-
snpRNA A6 (Figure 2A). To determine whether altered grow properties of the highly metastatic 
LNCaLN3 cells are associated with increased expression of PCS-snpRNA A6, we engineered 
LNCapLN3 cell variants stably expressing anti-sense variants of the PCS-snpRNA A6 (AS-PCS-
snpRNA A6). We found that expression of AS-PCS-snpRNA A6 did not affect growth of adherent 
cultures of LNCapLN3 cells in complete media (data not shown). In contrast, expression of AS-PCS-
snpRNA A6 markedly diminishes growth of LNCapLN3 cells in agar cultures and in androgen-
depleted media (Figure 2C, insets). 
Parental LNCap cells are poorly tumorigenic in vivo and are not capable of forming tumors in 
castrated mice. Remarkably, when we inoculated LNCap cells engineered to stably express PCS-
snpRNAs A6 (LNCap-A6 cells), all castrated mice developed rapidly growing, large tumors (Figure 
2D), which appear to grow faster in castrated animals compared to sham-operated controls. As 
expected, no tumors were detected in castrated mice after inoculation of parental or control-
transfected LNCap cells. These experiments demonstrate that stable expression of PCS-snpRNA A6 
9
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
06
9.
1 
: P
os
te
d 
27
 J
un
 2
01
1
in low-malignancy, hormone-dependent human prostate carcinoma cells confers castration-resistant 
phenotype and facilitates androgen depletion-independent growth. Collectively, our clinical and 
experimental findings presented in Figures 2 and 3 indicate that prostate cancer cells which will 
emerge in individuals expressing high level of the prostate cancer susceptibility snpRNAs are more 
likely to acquire the intrinsic ability to grow in androgen-low or androgen-free conditions and, 
therefore, this type of prostate cancer is more likely to progress early to hormone-independent, 
incurable, metastatic disease.
Q-PCR analysis reveals markedly increased levels of NLRP1-locus snpRNAs and 8q24-locus 
PCS-snpRNAs in tumor tissue samples from prostate cancer patients diagnosed with 
clinically-significant early-stage disease.
To facilitate evaluation of the clinical significance of discovered RNA molecules, we developed 
and validated Q-PCR-based method of quantitative analysis of snpRNA expression. Our Q-PCR 
method of snpRNA expression demonstrates excellent reproducibility for both NLRP1-locus snpRNAs 
(r2 = 0.808 for technical replicates) and 8q24-locus snpRNAs (r2 = 0.888 for technical replicates) and 
> 8,000-fold dynamic range of detection’s sensitivity in 3-5 ng of cDNA (Figure 3C). snpRNAs 
expression analysis in clinical PC samples reveals markedly increased snpRNA expression levels in 
tumor tissues compared to the adjacent normal prostate (Figure 3A and 3B). Notably higher 
expression levels of snpRNAs in human prostate adenocarcinoma samples and apparent association 
of increased snpRNA expression with pathohistological features of clinically-significant disease [122-
fold and 45-fold in stage 2, Gleason 7 tumors (p = 0.03); 370-fold and 127-fold in stage 2, Gleason 8 
tumors (p = 0.0001); for NLRP1-locus and 8q24-locus snpRNAs, respectively; Figure 3C] underscore 
potential translational relevance of our findings. Unexpectedly, we found a remarkably high 
correlation (r = 0.896; p < 0.0001) of expression levels of the NLRP1-locus snpRNAs and 8q24 ADIG-
locus snpRNAs (r2 = 0.803) in clinical PC samples (Figure 3C).  We conclude that Q-PCR analysis of 
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clinical samples reveals pathophisiological relevance of discovered snpRNA molecules by 
demonstrating: 1) markedly increased expression levels in prostate cancer; 2) association of 
increased expression levels with pathohistological features of the clinically aggressive disease; 3) 
highly concordant expression profiles of snpRNAs transcribed from genetic loci located at distinct 
chromosomes (17p13 and 8q24). Collectively, these data indicate the presence of a novel trans-
regulatory pathway which involves increased expression of intergenic snpRNAs transcribed from 
17p13 and 8q24 loci and suggest co-selection of these regulatory features in clinically-significant 
prostate cancer. 
snpRNAs are products of transcriptional activity of long-range intergenic enhancers. 
Several intergenic PC risk SNPs were mapped to functional enhancer elements in human cells 
(14-18) suggesting that snpRNAs are products of transcriptional activity of long-range enhancers. 
Consistent with this idea, widespread transcription of neuronal activity-regulated enhancers in mice 
has been documented recently (19). We thought to investigate whether the NLRP1-locus IDAGL may 
assert the detectable allele-specific functional effect on transcription by cloning distinct allelic variants 
of the chemically-synthesized 2 kb NLRP1 IDAGL region into the vector containing the firefly 
luciferase reporter, transfecting the purified experimental and control plasmids into target cells, and 
measuring the levels of luciferase activity. To control for transfection efficiency, the IDAGL-containing 
firefly luciferase reporter plasmids were co-transfected with plasmids containing a renilla luciferase 
reporter. We found that the presence of distinct allelic variants of IDAGL sequences significantly alter 
the expression of firefly luciferase (Figure 4), which suggest that IDAGL may function as SNP allele-
specific intergenic enhancers/insulators and affect the transcription of protein-coding genes. 
DNA/RNA complementarily rules suggest that snpRNAs may affect the activity of corresponding 
enhancer elements. Consistent with this idea, both enhancer and insulator activities of the NLRP1-
locus IDAGL are regulated by NLRP1-locus snpRNAs (Figure 4). The enhancer/insulator functions of 
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IDAGL/snpRNA feed-back regulatory loops appear specific because they are dependent on the SNP 
allele status of both DNA and RNA sequences (Figure 4 and data not shown). 
NLRP1-locus snpRNAs regulate expression of 14q32 locus microRNAs. 
Analysis of the predicted secondary structures of identified RNA molecules reveals that one of 
the notable common features of snpRNAs secondary structures is the presence of loop sequences 
which contain SNP-bearing 8-11 nt segments identical to primary sequences of microRNAs 
(Supplemental Figure S5). Intergenic snpRNA sequences contain multiple potential target sites for 
microRNAs which are often clustered around SNP nucleotides (Supplemental Figure S5). These data 
suggest that an epigenetic regulatory cross-talk between snpRNAs and microRNAs may exist with 
the potential down-stream effect on expression of protein-coding genes. Analysis of human cell lines 
engineered to stably express distinct allelic variants of the NLRP1-locus snpRNAs confirmed the 
validity of this hypothesis (4). Expression profiling experiments identify 36 microRNAs differentially 
regulated in BJ1 cells expressing distinct allelic variants of the NLRP1-locus snpRNAs (Figure 5 and 
Supplemental Figure S6). Analysis of genomic coordinates reveals that genes encoding 18 of 36 
(50%) NLRP1-locus snpRNA-regulated microRNAs are located within ~ 200 kb regions on 14q32 
which is immediately adjacent to the long non-coding RNA gene, MEG3 (Supplemental Figures S6-
S7). Thus, our analysis demonstrates that principal molecular targets for allele-specific trans-
regulatory actions of NLRP1-locus snpRNAs are clusters of microRNAs within a 200 kb segment of 
the 14q32 region which is adjacent to the snpRNA-targeted long non-coding RNA gene, MEG3. 
Detailed exploration of individual snpRNA-regulated transcripts shows that expression levels of 
distinct classes of non-coding RNAs are significantly altered in human cells engineered to stably 
express NLRP1-locus snpRNAs (Supplemental Figure S6). These results indicate that one of the 
important epigenetic features of snpRNA-mediated regulatory effects is genome-wide changes in 
expression of multiple diverse classes of non-coding RNAs documented examples of which include 
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snoRNAs and snoRNA-host genes (SNORD113; SNHG1; SNHG3; SNHG8); long non-coding RNAs 
(MEG3, HOTAIR, tncRNA, and MALAT1); microRNAs, microRNA-precursors, and protein-coding 
genes introns of which host microRNA genes (ATAD2; KIAA1199; Supplemental Figure S6). 
Allele affinity model of snpRNA-mediated regulation of microRNA expression and activity.
To understand the molecular basis of the regulatory cross-talk between snpRNAs and a 
diverse network of non-coding RNAs, we performed sequence homology profiling and structure-
functional analysis of relevant molecular entities. This analysis shows that snpRNA-regulated non-
coding RNAs manifest discernable homology/complementarity features of primary sequences. 
Notably, all 36 NLRP1-locus snpRNA-regulated microRNAs have at least one potential target sites 
within 152 nt sequence of the NLRP1-locus snpRNA molecule and many microRNA target sites 
manifest allele-associated changes of the minimal free energy (mfe) snpRNA/microRNA hybridization 
(Figure 5, Supplemental Figures S5 – S7). Comparisons of the allele-associated changes of the mfe 
values and experimentally-defined changes of the microRNA expression levels reveal a highly 
significant inverse correlation between these two variables that is lower mfe values appear to 
correspond to higher levels of microRNA expression (Figure 5 and Supplemental Figure S8). These 
results suggest a model of snpRNA-mediated regulation of microRNA expression according to which 
high affinity (low mfe) snpRNA alleles would facilitate increase abundance levels of corresponding 
microRNAs (Figure 5 and Supplemental Figure S8). 
Recent experiments demonstrate that let-7 microRNA release from complexes with Argonaute 
proteins and subsequent degradation can both be blocked by addition of microRNA target RNA which 
results in increase let-7 microRNA level (24). Computer modeling experiments demonstrate that let-
7b microRNA follows the pattern of allele-associated mfe changes characteristic of microRNAs 
expression levels of which are lower in G-allele expressing cells (Figure 5 and Supplemental Figure 
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S6D). We reasoned that if let-7 bioactivity model is valid for snpRNA-mediated effects on microRNAs, 
we should be able to detect the corresponding snpRNA allele-context-specific changes of the let-7b 
expression and activity in NLRP1-locus snpRNA-expressing cells. Consistent with this hypothesis, Q-
PCR experiments and luciferase reporter assays demonstrate that both expression and activity of the 
let-7 microRNA are significantly modified in RWPE1 cells genetically engineered to stably express 
NLRP1-locus snpRNAs (Figure 5 and Supplemental Figure S8D). We confirmed the validity of these 
conclusions by documenting similar relationships between snpRNA allele-context-specific mfe 
changes and effects on microRNA expression and activity for miR-205 microRNA (Figure 5 and 
Supplemental Figure S8D, bottom panels). Based on these observations, we propose that one of the 
mechanisms of snpRNA-mediated effects on microRNA-regulated processes is associated with 
snpRNA-allele-specific changes of microRNA abundance level and activity. The underlying molecular 
events are likely to resemble the let-7 bioactivity model according to which interaction of RNA 
molecules with microRNAs interfer with microRNA release from complexes with Argonaute proteins 
and prevent subsequent degradation of microRNA (24). 
NLRP1-locus snpRNA-regulated microRNAs recapitulate molecular features and biological 
phenotypes induced by snpRNAs. 
Microarray analysis demonstrates that epigenetic reprogramming of human cells following 
activation of  the NLRP1-locus snpRNA-regulated network of non-coding RNAs involves thousand’s 
down-steam protein-coding targets including 586 transcripts encoded by Polycomb-regulated bivalent 
chromatin domain genes (4) and 209 mRNAs encoded by human homologues of mouse genes 
flanking intergenic enhancers (data not shown). Collectively, these results as well as functional data 
support the model of sequential regulatory pathway of NLRP1-locus snpRNAs > microRNAs  > 
protein-coding transcripts. Further analysis of the regulatory circuitries of this network reveals 
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markedly altered expression of prostate susceptibility snpRNAs in cell lines genetically engineered to 
stably express either NLRP1-locus snpRNAs or snpRNA-regulated microRNAs (Figure 5 and 
Supplemental Figure S8). Results of these experiments demonstrate that:
1) Constitutive expression of NLRP1-locus snpRNAs enhances expression levels of several 
microRNAs (Figure 6 and Supplemental Figures S8 and S9) and induces expression of prostate 
cancer susceptibility snpRNAs (Figure 2 and Supplemental Figure S8);
2) Expression of cancer susceptibility snpRNAs is similarly induced in cells engineered to over-
express either NLRP1-locus snpRNAs or snpRNA-regulated microRNAs (Supplemental Figure S8);
3) Forced expression of selected snpRNA-regulated microRNAs recapitulate snpRNA-induced 
phenotypic changes in human cells such as the increased propensity for anchorage-independent 
growth in agar and enhanced clonogenic growth potential (Figure 6 and Supplemental Figure S8);
4) Microarray analysis of protein-coding transcripts in human cells engineered to over-express 
either NLRP1-locus snpRNAs or snpRNA-regulated microRNAs identifies common gene expression 
signatures (GES) expression profiles of which distinguishes highly metastatic human prostate 
carcinoma cell lines versus parental counterparts (Figure 6), clinical samples of distant metastatic 
lesions versus primary prostate tumors (Figure 6), and prostate cancer patients with significantly 
distinct likelihood of therapy failure after radical prostatectomy (Figure 6). 
Interestingly, forced expression of miR-205 recapitulate many molecular, phenotypic, and 
clinical features associated with expression of NLRP1-locus snpRNAs (Figure 6), including markedly 
decreased expression of the PTEN tumor suppressor. These data in conjunction with the 
experimental evidence of NLRP1-locus snpRNA-induced expression and activity of miR-205 in 
human cells (Figure 5) indicate that activation of the NLRP1-locus snpRNA/miR-205 axis may 
contribute to development of clinically-significant prostate cancer. 
Discussion
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GWAS identify highly significant SNP-phenotype associations (P<5x10-8) vast majority of which 
(80%) occurs within non-protein-coding sequences (1). These consistent and reproducible findings 
highlight a major knowledge gap in our understanding of phenotype-defining functions of human 
genome segments lacking protein-coding potentials. Our experiments reveal widespread transcription 
at IDAGL raising the possibility that non-protein-coding RNA molecules may play an important role in 
predisposition to multiple common human disorders. We demonstrate that forced expression of 52 nt 
snpRNAs imposes castration-resistant phenotype on human prostate carcinoma cells. It transforms 
low-malignancy, hormone-dependent human prostate cancer cells into highly malignant, androgen 
depletion-independent prostate cancer. To facilitate the assessment of clinical significance of 
discovered snpRNAs, we developed Q-PCR method of quantitative analysis of snpRNAs and 
validated its utility by analysis of snpRNA expression in clinical samples. Our analysis reveals 
markedly elevated snpRNA expression levels in prostate cancer tissues compared to the adjacent 
normal prostate (Figure 3). Notably higher expression levels of snpRNAs in human prostate 
adenocarcinoma samples and apparent association of increased snpRNA expression with 
pathohistological features of clinically-significant disease (high Gleason score) highlight potential 
translational relevance of our findings. Collectively, our data imply that prostate cancer cells which 
emerge in individuals expressing high levels of the prostate cancer susceptibility snpRNAs are more 
likely to progress early to hormone-independent, incurable, metastatic disease. Our work defines the 
intergenic 8q24 region as ADIG-regulatory locus of critical significance for human prostate cancer, 
reveals previously unknown molecular links between the innate immunity/inflammasome system and 
development of hormone-independent PC, and identify novel diagnostic and therapeutic targets 
successful validation of which should be highly beneficial for clinical management of prostate cancer 
patients. 
Our experiments demonstrate that IDAGLs represent multifunctional genomic trans-regulatory 
domains possessing broad-range of intrinsic regulatory functions which are mediated by both DNA 
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sequences and transcribed RNA molecules. Many IDAGLs harbor a consensus chromatin signature 
comprising H3K27Me3 and H3K4Me1 histones, Ezh2, and disease-state-specific panels of 
transcription factors. IDAGL’s functions as cell-type-specific long-range enhancers or insulators 
appear dependent on the allelic status of a disease-linked SNP and are regulated by snpRNAs. Our 
experiments indicate that microRNAs which have complementary sequences in corresponding 
snpRNAs may constitute one of the primary targets of snpRNA-induced genome-wide epigenetic 
regulatory networks engagement of which is triggered by distinctive single-base-level molecular 
recognition events (Supplemental Figure S8). Altered microRNA expression and activity would 
facilitate an epigenetic amplification of a single-base-driven regulatory event by inducing down-stream 
mRNA expression changes of many (perhaps, thousands) protein-coding genes which would 
ultimately cause clinically significant alterations of cellular functions. Examples of experimentally 
identified components of such a regulatory network are key inflammasome/innate immunity pathway-
related genetic targets (4). In agreement with this mechanism, we found markedly altered expression 
of prostate cancer susceptibility snpRNAs in cell lines genetically engineered to stably express either 
NALP1-locus snpRNAs or snpRNA-regulated microRNAs (Figure 2 and Supplemental Figure S8). 
Further, our data suggest that microRNAs may contribute to biogenesis of snpRNAs by guiding 
Argonaute family-endonucleases to execute a sequence-specific cleavage of snpRNAs and putative 
small snpRNA-precursors, long non-coding snpRNAs. Consistently, we found that many small 
snpRNAs exhibit cell type specific expression profiles, whereas long non-coding snpRNAs containing 
disease-associated SNP sequences manifest more ubiquitous expression patterns (4). These 
observations indicate that small snpRNAs may represent products of a cell type-specific processing 
of long non-coding snpRNAs and support the hypothesis that microRNAs are intrinsic regulatory 
components of snpRNA/enhancer IDAGL networks which are contributing to maintenance of 
epigenetic regulatory state in a cell.
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Our experiments indicate that activation of the NLRP1-locus snpRNA/miR-205 axis may 
contribute to development of clinically-significant prostate cancer by reducing expression of the PTEN 
tumor suppressor. We found that NLRP1-locus snpRNAs induce expression and activity of miR-205 
in human cells (Figure 5) and forced expression of miR-205 recapitulate many molecular, phenotypic, 
and clinical features associated with expression of NLRP1-locus snpRNAs (Figure 6), including 
markedly decreased expression of the PTEN tumor suppressor. PTEN tumor suppressor has been 
identified as a target for miR-205 based on target prediction algorithms and miR-205 overexpression 
experiments using the pGL3-PTEN 3’UTR reporter constructs with mutations of miR-205-binding 
sites, microarray and TaqMan Q-PCR analyses, and western blot analysis (25). Altered expression 
and activity of miR-205 have been associated with epithelial-to-mesenchymal transition (EMT), 
emergence of stem cell-like properties, and maintenance of mammary epithelial cell progenitors (25-
27). 
Results of our experiments are highly consistent with the emerging concept of the pervasive, 
global transcriptional activity of human genomes which is supported by observations that vast 
majority of transcripts in human cells is represented by non-coding RNAs (28-37; see Supplemental 
text for discussion and additional references). Collectively, they lend credence to the idea that 
intergenic DNA sequence variations may contribute to disease pathogenesis via non-coding RNA 
intermediaries which assert trans-regulatory effects on epigenetic regulatory circuitry of a cell. This 
concept challenges the dominant position of protein-centric experimental paradigm that is focused on 
analysis of effects of genetic variations on protein-coding genes within or near boundaries of which 
the genetic variants are located. Conclusive evidence of ubiquitous expression in human cells of 
intergenic disease-associated genetic loci indicates the potential clinical benefits of the concurrent 
analyses of DNA sequences and expression profiling of corresponding RNA products. This is critically 
important because the transcriptional activity and transcript abundance levels are genetically-defined 
quantitative traits assessment of which should enhance the disease risk prediction power of 
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corresponding genetic tests. We anticipate that reported here findings should have a major near-term 
implication on design and execution of genome-wide association studies and follow-up mechanistic 
studies of non-protein-coding disease-linked loci. To this end, we provide sequences of validated 
primers and experimental protocols (Supplemental Tables S1-S5) to facilitate the immediate 
implementation of this type of analyses for 96 intergenic SNPs associated with increased risk of 
developing 21 common human disorders. 
Methods
Detailed description of all aspects of the experimental procedures, including snpRNAs and microRNA 
isolation and activity analysis; microRNA expression analysis; Cell Staining and Flow Cytometry; 
Induced Differentiation of THP-1 cells; Lentivirus Production and Generation of Stably Transfected 
BJ1, RWPE1, U937, and THP-1 cells; Colony Growth and Clonogenic Growth Assays; can be found 
in the online Supplement and previous publications (4). Supplemental information is available at 
http://www.genlighttechnology.com 
Cell Lines
Human BJ1, U937, THP-1, RWPE1, and HME1 cell lines were obtained from ATCC. hTERT-
immortalized BJ1, LNCap, and LNCapLN3 cells were previously described (38-42). 
Tumor Cell Xenografts.  Sub-confluent monolayers of control LNCaP or LNCaP-A6 cells were 
trypsinized and counted, then resuspended in RPMI-1640 medium with 25% charcoal-dextran 
stripped-fetal bovine serum (CDS-FBS) and 50% (vol/vol) 2 X Matrigel (Millipore, Inc., Billerica, MA). 
Aliquots (250 μls) containing 106 cells were then injected subcutaneously in the flanks of 8-week male 
NCR Nu/Nu mice (Taconic, Inc.) that had been surgically castrated 10 days prior through a scrotal 
incision under anesthesia or sham-castrated involving the scrotal incision without removal of the 
testis.  Tumor size was estimated from largest diameter (a), smallest diameter (b) and height (c) 
measurements with calipers with tumor volume calculated using the formula V = π/6 x a x b x c.  Mice 
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were euthanized at the end of the experiments, tumors were surgically recovered, weighted, and 
processed for pathological and molecular analyses. 
Microarray gene expression analysis
Technical and analytical aspects as well as stringent QC and statistical protocols of gene expression 
analysis experiments was carried-out essentially as described in our published work (39-42). Briefly, 
the array hybridization and processing, data retrieval and analysis was carried out using standard 
sets of the Affymetrix equipment, software, and protocols in state-of-the-art Affymetrix microarray 
core facility. RNA was extracted from cell cultures of two independent biological replicates of each 
experimental condition and analyzed for sample purity and integrity using BioAnalyzer (Agilent). 
Expression analysis of 54,675 transcripts was carried out for each sample in duplicates using 
Affymetrix HG-U133A Plus 2.0 arrays. Data retrieval and analysis was performed using MAS5.0 
software and concordant changes of gene expression for each experimental condition were 
determined at the statistical threshold p value < 0.05 (two-tailed T-test). All microarray analysis data 
are publicly available coincidently with the date of publication. 
Protocols for identification of endogenous trans-regulatory RNAs 
(Detailed descriptions of protocols A - E are presented in the Supplement)
1. Extract small RNA from cells using mirVana isolation kit (protocol A)
2. Detect if there is DNA contamination by performing PCR using extracted RNA as template and β-
actin primers (protocol B)
3. Synthesize cDNA from extracted small RNA (protocol C)
4. Perform first-round PCR using appropriate primer set (protocol B)
5. Clean up PCR product and evaluate cleanup PCR product on 1.2% gel (protocol D)
6. Perform nested PCR using purified product of the first-round PCR as template and appropriate 
primer set; evaluate nested PCR product on 1.2% gel (protocol B)
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7. Cut the single DNA band of interest from the gel, extract and purify the product for sequencing 
(protocol E)
Luciferase reporter assays
Luciferase reported assays were carried-out to identify allele-specific features of SNP-bearing RNA 
and DNA sequences. Enhancer/insulator activities of the 2 kb intergenic DNA sequence containing 
distinct allelic variants of the rs2670660 NLRP1-locus SNP. Luciferase reporter assays to assess the 
enhancer activity of 2 kb NALP1-locus intergenic region was carried out in RWPE1 and HEK293 cells 
transiently expressing either control luciferase reporter plasmids or plasmids containing chemically 
synthesized 2 kb sequences flanking distinct allelic variants of the NLRP1-locus intergenic SNP 
rs2670660, which is positioned exactly in the middle of the enhancer’s sequence. Because allelic 
differences in the luciferase reporter assays tend to be modest, measurements were controlled by 
multiple replications of all experimental elements of the enhancer assay. We considered the 
possibility of multiple levels of variations, including plasmid preps, transfection replicates (along with 
transfection efficiency measurements, such as using the Renilla lucferase co-transfection controls for 
normalization). At least three independent experiments were carried out for each setting and three 
replicates of the luciferase assay were performed in each experiment.  Results were validated using 
at least two independent plasmid preps to control for this potentially significant source of variation. 
Statistical and Bioinformatics Analysis 
Detailed protocols for data analysis and documentation of the sensitivity, reproducibility, and other 
aspects of the quantitative statistical microarray analysis using Affymetrix technology have been 
reported previously (39-42). Forty to sixty percent of the surveyed genes were called present by 
Affymetrix Microarray Suite version 5.0 software in these experiments. The concordance analysis of 
differential gene expression across the data sets was performed using Affymetrix MicroDB version 
3.0 and DMT version 3.0 software as described previously (39-42). We processed the microarray 
data using the Affymetrix Microarray Suite version 5.0 software and performed statistical analysis of 
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the expression data set using the Affymetrix MicroDB and Affymetrix DMT software. The Pearson 
correlation coefficient for individual test samples and the appropriate reference standard were 
determined using GraphPad Prism version 4.00 software (GraphPad Software). We calculated the 
significance of the overlap between the lists of differentially-regulated genes by using the 
hypergeometric distribution test (43). Analyses of the predicted secondary structures of identified 
snpRNAs, screening for potential target sites of microRNAs, and sequence homology profiling of 
snpRNAs and microRNAs were performed using web-accessible publicly available resources 
(http://rna.tbi.univie.ac.at/cgi­bin/RNAfold.cgi; http://www.ncrna.org/centroidfold/; http://bioinfo.uni­
plovdiv.bg/microinspector/; http://www.mirbase.org/). 
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Figure Legends
Figure 1. Constitutive expression of distinct allelic variants of NLRP1-locus snpRNAs exerts allele-
specific clinically-relevant effects on phenotypes of human cells. 
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A, THP-1 cells were engineered to stably express distinct allelic variant of the NLRP1-locus 
snpRNAs and induced to differentiate into macrophages. Efficiency of the monocyte/macrophage 
trans-differentiation was assessed by analysis of viable and apoptotic cells (top panels) and 
measurements of the number (bottom panels) and phagocytic activity (inset, bottom panel) of 
macrophages. Note that in response to induction of differentiation, THP-1 cells expressing pathology-
linked G-allele snpRNAs undergo massive apoptosis and produce ~ 5-fold less macrophages which 
are twice less potent in the sheep erythrocyte phagocytosis assay compared to macrophages derived 
from THP-1 cells expressing ancestral A-allele snpRNAs. 
B, Pathology-linked G-allele expressing human fibroblast BJ1 cells manifest significantly higher 
motility compared to ancestral A-allele expressing BJ1 cells. Gaps of defined distances were created 
in confluent cultures of BJ1 cells and motility sequences were continuously monitored and recorded 
using time-lapse video cinematography. For each culture, the initial distance, motility sequence time 
(time to complete closing of the gap), and motility speed were measured. Average values of six 
replicate measurements are reported. 
C, Human NLRP1-locus snpRNAs manifest allele-specific biological activities in mouse 
macrophages (top left set of bar graphs) and mouse mesenchymal cells (top right set of bar graphs; 
inset shows results of the similar assay in human mesenchymal cells), which recapitulate the 
corresponding allele-specific biological activities in human cells. Bottom set of bar graphs shows the 
biological activities of synthetic 19 nt LNA-oligonucleotide-based structural analogues of the allele-
specific variants of NAPL1-locus snpRNAs which were assessed using THP-1 
monocyte/macrophages transdiferentiation assays. Note that synthetic LNA-analogues recapitulate 
the allele-specific patterns of NLRP1-locus snpRNA bioactivities mimicking effects on macrophage 
numbers (left) and phagocytic activity (right).
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Figure 2. Expression of PCS-snpRNAs induces androgen depletion-independent and castration-
resistant phenotypes of human prostate cancer.
A. Expression of 8q24 PCS-snpRNAs (red arrows) is induced by NLRP1-locus snpRNAs (top 
gel image), is increased in highly metastatic PC cells and circulating tumor cells (CTC) from 
orthotopic human PC xenografts (bottom gel images). Prostate cancer susceptibility snpRNAs A6 
(rs16901979) manifest increased expression in highly metastatic human prostate carcinoma cells 
(LNCapLN3, PC3-21) and asserts biologically and clinically-relevant effects on growth of hormone-
dependent human prostate carcinoma cells LNCap. RT-PCR analysis demonstrates low expression 
of prostate cancer susceptibility snpRNAs A6 in normal human prostate epithelial cells RWPE1 and 
markedly higher expression level in LNCapLN3 cells, which were selected in vivo for increased 
metastatic potential by serial orthotopic implantation of parental, poorly metastatic LNCap cells. 
Similarly, expression of multiple PCS-snpRNAs is elevated in blood-borne human prostate carcinoma 
metastasis precursor cells PC-3-21 compared to the parental cell line PC-3. P values of the 
corresponding experimental setting versus control experiments are shown. 
B, Hormone-dependent human prostate carcinoma LNCap cells engineered to stably express 
the prostate cancer susceptibility snpRNA A6 acquired ability to survive and grow in androgen-
depleted media (set of bars in the top right panel). Note that growth pattern in androgen-depleted 
media of LNCap cells expressing prostate cancer susceptibility snpRNA allele became similar to 
highly metastatic LNCapLN3 cells (set of bars in the bottom right panel). Set of bars in the bottom left 
panel shows the increased survival and growth in androgen-depleted media of LNCap cells 
constitutively expressing A-alleles of NLRP1-locus snpRNAs. Set of bars in the top left panel shows 
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the results of the Q-PCR analysis of the expression of PCS-snpRNA A6 in RWPE1 normal prostate 
epithelial cells engineered to stably express distinct allelic variants of the NLRP1-locus snpRNAs. 
C, Hormone-dependent human prostate carcinoma LNCap cells engineered to stably express 
the prostate cancer susceptibility snpRNA A6 acquired markedly higher anchorage-independent 
clonogenic growth potential in agar (top figure) and ability to survive and grow in androgen-depleted 
media (bottom figure). Note that growth potentials in both agar cultures and androgen-free media of 
LNCap cells expressing prostate cancer susceptibility A-allele of snpRNA A6 are significantly higher 
compared to LNCap cells expressing ancestral C-allele. Transfection of anti-sense alleles of PCS-
SNP RNA A6 (asA6) diminishes clonogenic growth in agar (inset in top figure) and survival and 
growth in androgen-depleted media of highly metastatic LNCapLN3 human prostate carcinoma cells 
(inset in bottom figure). 
D. Inoculation of hormone-dependent, low-malignancy human prostate carcinoma LNCap cells 
engineered to stably express prostate cancer susceptibility snpRNA A6 (LNCap-A6 cells) induces 
rapidly growing tumors in castrated mice (left figures). Note that tumors in castrates appear larger and 
growing faster compared to the sham-operated mice (right figures). No tumors were detected in either 
castrate or shame-operated groups within the indicated observation periods after inoculation of 
parental or control-transfected LNCap (insets). Bottom set of figures show images of cultured in vitro 
in androgen-depleted media of LNCap-A6 cells which were recovered from tumors in castrated mice.
Figure 3. Increased expression of NLRP1-locus snpRNAs and PCS-snpRNA A6 in clinical prostate 
carcinoma samples.
A, B, Q-PCR analysis reveals markedly increased expression of NLRP1-locus snpRNAs (A) 
and PCS-snpRNA A6 (B) in clinical PC samples compared to adjacent normal prostate (far left set of 
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bars in each panel). Note the apparent correlation of the expression levels with the stage (top panels) 
and Gleason scores (bottom panels). Each data set is shown in two different scales to account for 
markedly distinct PCS-snpRNA expression levels in different group of samples. Each bar shows the 
actin-normalized value of the expression level of corresponding snpRNAs in samples from individual 
patients as determined by the Q-PCR analysis. Shaded areas highlight the thresholds of expression 
levels exceeding 99% confidence intervals defined by the expression levels in adjacent normal 
prostate samples. 48 pathologist-verified clinical samples of the OriGene TissueScan Cancer qPCR 
Arrays Prostate Cancer Panel III were analyzed in accordance with the supplier’s protocols. QC data, 
pathology reports, and associated clinical information are available at 
http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx. 
C, Correlation plots and linear regression analyses documenting reproducibility of technical 
replicates of the Q-PCR analysis of the expression levels of PCS-snpRNA A6 (top left figure; r = 
0.899; p < 0.0001) and NLRP1-locus snpRNA (top right figure; r = 0.942; p < 0.0001). Bottom left 
figure illustrates highly significant correlation of the expression of NLRP1-locus snpRNA and PCS-
snpRNA A6 in prostate tumor samples from patients diagnosed with prostate adenocarcinoma (r = 
0.896; p < 0.0001). Bottom right figure shows the average expression values of the PCS-snpRNA A6 
and NLRP1-locus snpRNA in adjacent normal prostate samples and prostate cancer samples from 
tumors with different Gleason scores. Note markedly higher average expression levels of snpRNAs in 
tumor samples with high Gleason scores and increasing proportion of patients in high Gleason score 
groups with snpRNA expression levels exceeding thresholds of 99% confidence interval defined by 
the expression levels in adjacent normal prostate samples. Inset illustrates these relationships within 
the 400X scale of fold expression changes normalized to the average expression values in adjacent 
normal prostate samples. 
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Figure 4. Identification and characterization of genomic trans-regulatory domains (GTRDs) which are 
located in intergenic disease-associated genetic loci (IDAGL), manifest enhancer/insulator activities, 
and transcribe biologically active snpRNAs. 
A. Chromatin state map analysis of the intergenic disease-associated genomic region 
transcribing NLRP1-locus snpRNA rs2670660. Boxed areas depict the locations of the NLRP1 
promoter (red box) and two intergenic enhancers (blue boxes), one of which is characterized in this 
study and shown at higher resolution in the bottom figure. Positions of disease-linked SNP 
nucleotides within snpRNA-encoding sequences are indicated by vertical lines. Chromatin state maps 
of individual snpRNA-encoding genomic sequences in human embryonic stem cells are visualized 
using the custom tracks of the UCSC Genome Browser  (http://genome.ucsc.edu/ENCODE/ ). Color-
coded horizontal lines depict alignments of DNA sequences derived from Chip-Seq experiments 
using antibodies against corresponding proteins. Individual zoom-in chromatin state maps aligned to 
corresponding snpRNA-encoding sequences are shown with the corresponding disease-linked SNPs 
(Supplemental Figures 2-4). Original experiments describing the corresponding mouse and human 
genome-wide chromatin state maps were reported elsewhere (6). 
B. Luciferase reported assay reveals allele-specific enhancer/insulator  activities of the 2 kb 
intergenic DNA sequence containing distinct allelic variants of the rs2670660 NLRP1-locus SNP. 
Luciferase reporter assay to assess the enhancer activity of 2 kb NLRP1-locus intergenic region was 
carried out in RWPE1 (set of bars in left top panel) and HEK293 set of (set of bars in the right top 
panel) cells transiently expressing either control luciferase reporter plasmids or plasmids containing 
chemically synthesized 2 kb sequences flanking distinct allelic variants of the NLRP1-locus integenic 
SNP rs2670660, which is positioned exactly in the middle of the enhancer’s sequence.  Note 
decreased enhancer’s and insulator’s activities in ancestral A-allele constructs compared to 
pathology-linked G-allele constructs. Bottom panels of bars show the effects of NLRP1-locus 
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snpRNAs on enhancer and insulator activities in RWPE1 cells. Note that distinct alleles of the 
NLRP1-locus intergenic enhancer manifest different responses to the NLRP1-locus snpRNAs: 
enhancer’s activities in ancestral A-allele constructs are completely blocked compared to pathology-
linked G-allele constructs. 
C. Molecular anatomy of the network of intergenic long-range enhancers (iLREs) and 
snpRNAs facilitating castration-resistant phenotype of human prostate cancer. NLRP1-locus 
snpRNAs, which are transcribed from the intergenic long-range enhancer sequence located in 17p13 
region at ~ 30 kb distance from the NLRP1 gene,  regulate expression level of 8q24-locus PC 
susceptibility snpRNAs (bottom gel images and Figure 2), which are transcribed from intergenic 
enhancers located in the prostate cancer susceptibility regions 1, 2, and 3 (middle figures). Activity of 
the iLRE containing PCS SNP rs6983267 is increased 15-20-fold by the co-transfection of beta-
catenin/TCF4 transcription factors, expression of which is significantly elevated in RWPE1 cells 
engineered to constitutively express NLRP1-locus snpRNAs (sets of bars in inset). In contrast, 
expression of antagonists of beta-catenin, DACT3 and DCAT1, is decreased in NLRP1-locus 
snpRNA-expressing cells. References to the original publications reporting chromatin state maps, 
activity of intergenic enhancers, and identification of trans-regualtory snpRNAs of the 8q24 prostate 
cancer susceptibility regions 1, 2, and 3 are indicated and discussed in the main text. 
D. Graphical representations of the reported in the Supplemental Table S10 and Supplemental 
Figure S4 chromatin state maps of 43 IDAGLs. Areas highlighted in red and blue indicate disease-
type-specific transcription factor signatures which appear associated with sets of pathogenetically- 
and/or epidemiologically-related disorders. Each column represents the individual IDAGL containing 
an SNP associated with a particular trait or disease phenotype. Each row corresponds to the 
individual chromatin state marker protein. Last row shows a cumulative chromatin state score 
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indicating how many proteins were bound in close proximity of the corresponding SNPs. Visualization 
and links to original experimental data are publicly available (http://genome.ucsc.edu/ENCODE/ ). 
Figure 5. snpRNA sequences represent allele-specific “decoy” targets of microRNAs which function 
as SNP-allele-specific enhancers of microRNA expression and activity.
A - E. Experimental evidence and computational analysis supporting the allele affinity model of 
snpRNA-mediated regulation of microRNA expression and activity. 
A. ABI TaqMan PCR-based screen identifies a statistically significant set of 36 microRNAs 
expression of which is altered at least 1.5-fold in NLRP1-locus snpRNA-expressing cells compared to 
control BJ1/EGFP cells and differentially regulated in pathology-linked G-allele-expressing BJ1 cells 
compared to the ancestral A-allele-expressing cells (set of bars in the top left panel). Note that 18 of 
36 (50%) of these microRNAs are derived from the single microRNA cluster on ~ 200 kb continuous 
region of 14q32 band of chromosome 14, which suggest that 14q32 cluster microRNAs may be 
primary molecular targets of the NLRP1-locus snpRNAs (Supplemental Figure S6). Microarray 
analysis of human BJ1 cells engineered to stably express distinct allelic variants of the NLRP1-locus 
transRNAs reveals allele-specific alterations of expression levels of multiple distinct classes of non-
coding RNAs which include snoRNAs and snoRNA-host genes (SNORD113; SNHG1; SNHG3; 
SNHG8), long non-coding RNAs (MEG3, tncRNA, HOTAIR, and MALAT1), microRNAs, microRNA-
precursors, and protein-coding microRNA-host genes (ATAD2; KIAA1199). Note that changes of 
expression of intron-residing microRNAs miR-548d (intron of the ATAD2 gene) and miR-549 (intron of 
the KIAA1199 gene) are in good correspondence with allele-specific expression levels of 
corresponding microRNA-host genes which suggest a coordinated mechanism of regulation 
(Supplemental Figure S6). 
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A-D, Expression of high affinity (low mfe) snpRNA alleles in human cells (defined by allele-
specific changes in minimal free energy (mfe) of snpRNA/microRNA hybridization) is associated with 
increase in abundance levels of corresponding microRNAs. A, Statistically highly significant inverse 
correlation between allele-specific changes in minimal free energy (mfe) of snpRNA/microRNA 
hybridization and experimentally-defined changes of microRNA expression that is lower mfe values 
correspond to higher levels of microRNA expression (A, set of bars in the top right panel). These 
relationships are shown for individual microRNAs the abundance levels of which in human cells are 
induced (miR-302a; miR-629; miR-548d; miR-126; miR-770-5p; Figure B) or repressed (miR-20b; let-
7b; miR-133a; miR-205; Figure C) by forced expression of pathology-linked G-allele snpRNAs 
compared to ancestral A-allele-expressing cells. Inset bars show the results of Q-PCR analysis of 
expression of corresponding microRNAs (see additional analysis and examples in the Supplement 
and Supplemental Figure S8). 
E, Expression of NLRP1-locus snpRNAs in human cells induces allele-sequence-dependent 
changes in expression (top sets of bars) and activity (bottom sets of bars) of microRNAs. Q-PCR 
measurements of the expression levels and luciferase reporter assay of miR-205 and let-7b activities 
in RWPE1 cells stably expressing distinct allelic variants of the NLRP1-locus snpRNAs demonstrates 
significant changes of expression and activity of both microRNAs in high affinity (A-allele) snpRNA-
expressing cells compared to low affinity (G-allele) snpRNA-allele-expressing cells. 
Figure 6. Regulatory cross-talk between NLRP1-locus snpRNAs, 8q24-locus PCS-snpRNAs, and 
snpRNA-regulated microRNAs induces similar clinically-relevant phenotypes in human cells. 
A, Q-PCR analysis of microRNA expression in human cells engineered to constitutive express 
NLRP1-locus snpRNAs identifies concordant SNP-allele-sequence-specific changes of expression 
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levels of three microRNAs, miR-375, miR-20b, miR-205 expression of which increased in human 
embryonic stem cells and blood-borne human prostate carcinoma metastasis precursor cells 
(Supplemental Figure S10). Human cell lines engineered to constitutive express NLRP1-locus 
snpRNAs manifest altered expression profiles of PCS-snpRNAs (Figure 2; induced PCS-snpRNAs 
are marked with red arrows) and expression levels of three stemness microRNA (miR-375, miR-20b, 
miR-205). 
A-B,  Human cells engineered to constitutive express NLRP1-locus snpRNA-regulated 
stemness microRNAs (miR-375, miR-20b, miR-205) manifest dramatic changes of anchorage-
independent growth in agar (RWPE1 cells; Figure A, bottom panel) and clonogenic growth potential in 
clonogenicity assays (BJ1 cells; Figure B). These microRNA-induced phenotypic changes 
recapitulate phenotypes of human cells engineered to constitutively express NLRP1-locus snpRNAs 
and PCS-snpRNAs (Figures 1 & 2; Supplemental Figure S9; and ref. 4). 
C-E, Microarray analysis reveals activation of snpRNAs/miR-205 axis in human prostate 
cancer. Microarray expression profiling experiments identify a set of 47 transcripts manifesting highly 
concordant expression profiles (r = 0.705; P < 0.0001) in RWPE1 human prostate carcinoma cells 
engineered to stably express either microRNA miR-205 or NLRP1-locus snpRNAs, in blood-borne 
human prostate carcinoma metastasis precursor cells of PC3 lineage, and in highly metastatic 
variants (LNCapLN3; LNCap-C4-2; LNCap-C4-2B) of LNCap lineage (C). 
D, Refinement of the 47-transcript signature to yield individual Pearson correlation coefficients 
> 0.5 in highly metastatic cell lines and < - 0.6 in parental and less metastatic variant LNCapPro5 (top 
sets of bars) generates the 30-gene expression signature which manifest highly concordant 
expression profiles in clinical samples of distant metastatic lesions (bottom sets of bars) compared to 
normal prostate samples (p = 1.1E-11), histologically normal prostate tissue samples adjacent to 
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tumors (p = 5.1E-21), and primary prostate tumors (p = 3.0E-18). Multivariate Cox regression analysis 
of the 30 genes comprising the miR-205 signature identifies highly significant 16-gene therapy failure 
prediction model (Chi Square = 47.1919; p = 0.0001); Kaplan-Meyer analysis of clinical samples from 
79 prostate cancer patients with known clinical outcomes after radical prostatectomy (39, 41) using 
weighted survival prediction algorithm (39) demonstrates that patients with distinct expression profiles 
of the 16-gene miR-205 signature have statistically distinct probability of therapy failure (Log rank 
test: Chi Square = 64.67; p < 0.0001; Figure E). Note that all patients (100%) in the top quartile failed 
therapy; in contrast, only 16% of patients in the bottom quartile failed therapy within 5 years after 
radical prostatectomy. 
Figure 1. 
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Figure 2. 
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Figure 3.
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Figure 4.
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Figure 5.
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Figure 6.
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